This is a single arm, phase II study. Advanced BTC patients who have been previously treated with immunotherapy in either the 2nd or 3rd line will be enrolled.~Patients will be treated with AZD6738 and Durvalumab combination.~One cycle consists of 4weeks. Response evaluation will be done every 8 weeks (every 2 cycles) of treatment~Tumor biopsy is mandatory: screening, after 8weeks (1st-response evaluation), at disease progression (PD)~blood sampling for biomarker study is mandatory: every cycles~To evaluate the metabolic changes by AZD6738 and Durvalumab combination : 18 F-FDG PET is mandatory : screening, after 8 weeks (1st-response evaluation)
This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line.~Patients will be treated with AZD6738 and Durvalumab combination.